Elanco Animal Health Incorporated (ELAN) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, ELAN scores 47 out of 100 with a letter grade of D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

• Fundamental Cash Engine: 9 / 20. Per the RQD rating, this pillar reflects ROIC of -2.5% and an FCF yield of 2.45%. Negative ROIC means the business is not currently earning returns above its capital base, a core weakness for a prospective buyer assessing whether growth is value-creating.
• Whale / 13F Flow: 11 / 20. Per the RQD rating, this pillar covers institutional accumulation and options positioning. The source data contains no 13F detail (see Analyst View section), so the score cannot be traced to specific holders.
• Insider Conviction: 12 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. No underlying insider transactions are provided in the source data.
• Macro Regime Fit: 5 / 20. Per the RQD rating, this is the lowest pillar, reflecting a beta of 0.96 and sector sensitivity. A beta near 1.0 means the stock is expected to move roughly in line with the broad market, so this score points to weak alignment with the current macro regime rather than volatility risk.
• Forensic Balance Sheet: 10 / 20. Per the RQD rating, this reflects an Altman Z of 1.24, Piotroski F of 7/9, and Debt/Equity of 0.44. The Piotroski reading is comparatively strong, but the Altman figure sits in a range generally treated as distress-adjacent, which weighs on the score.

Translating these into investor implications: the RQD profile shows a company whose operating economics are currently negative (ROIC -2.5%, net margin -4.9%) with only moderate balance sheet support. Upside drivers would need to come from margin recovery and sustained free cash flow; the forward P/E of 20 implies the market is already pricing in some earnings improvement relative to trailing EPS of -0.46. The valuation tradeoff is that a positive forward multiple on negative trailing earnings depends heavily on that recovery materializing. The low Macro Regime score suggests limited tailwind from sector positioning. This is an educational reading of the rating, not personalized advice.

Elanco Animal Health Incorporated is a NYSE-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The profile identifies the company as operating in animal health. Specific product lines, customer segments, and revenue mix are not available in source data. The company carries a market capitalization of $11.6B per the profile.

Per the SEC financials, revenue rose from $4417.0M in FY 2023 to $4715.0M in FY 2025, while operating income swung from $398.8M in FY 2024 to $-273.8M in FY 2025. Per the market data, gross margin is 55%, operating margin is -6%, and net margin is -4.9%, with ROIC at -2.5%. Per the RQD rating, the Altman Z-Score is 1.24 and the Piotroski F-Score is 7/9, with Debt/Equity at 0.44. Reported debt declined from $4277.0M in FY 2024 to $3064.9M in FY 2025 while cash rose to $545.0M.

Per the recent news and catalysts feed, six items reference ELAN. Five are tagged as market wire and one as a catalyst. The catalyst-tagged item carries a GREEN light, a Yahoo Finance report on whether ELAN will beat estimates in its next earnings report. Four other items are general market-action summaries from Yahoo! Finance Canada, TradingView, Stock Titan, and Simply Wall St, each flagged YELLOW. A Yahoo Finance earnings preview ("Earnings Expected to Grow") is also flagged YELLOW. The feed does not disclose specific earnings figures, guidance, or event details. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are mapped for ELAN.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations are not available in source data. Investors should note that the absence of mapped links is a data gap, not evidence of an absence of dependencies.

• What are the specific drivers of the FY 2025 swing from positive operating income in FY 2024 to a negative operating result?
• What are the trailing P/E and EV/EBITDA values, which the source data marks as unavailable?
• What specific institutional, insider, or Congressional transactions underlie the whale and insider pillar scores?
• What is the company's debt maturity profile and interest coverage, given the reported debt of $3064.9M against cash of $545.0M?
• Which upstream suppliers and downstream customers drive revenue, and how exposed is the business to them?